Drug screening was carried out using nutlin-3a, afatinib, MEK1/2 inhibitor III, AKT inhibitor VIII, 5‑FU, doxorubicin, and SN‑38. Drug dilutions were performed in two series: 1) stepwise 2‑fold dilutions from 20 µM to 19.5 nM; and 2) stepwise 2‑fold dilutions from 15 µM to 29.3 nM.
